Unosource Pharma

Mumbai, India Founded: 2013 • Age: 13 yrs Listed
Pharmaceutical manufacturing, exporting, and CDMO services.
Request Access
Report Incorrect Data
Page last updated

About Unosource Pharma

Unosource Pharma is a publicly listed company based in Mumbai (India) founded in 2013. Pharmaceutical manufacturing, exporting, and CDMO services. The company has 1,563 employees. Its Indian entity Akums Drugs And Pharmaceuticals Limited reported revenue of ₹4,488 Cr. Unosource Pharma offers products and services including Pharmaceutical Formulations and Nutraceuticals. Its focus areas include Nutraceuticals, Wellness Products, Supplements and Pharmaceuticals.

Company details

Akums Drugs and Pharmaceuticals Ltd. is recognized as a leading CDMO in the pharmaceutical sector, where operations are supported by advanced manufacturing facilities and RD capabilities. Products are exported to over 65 countries, with a focus on formulations for pharmaceuticals, nutraceuticals, and cosmetics. Compliance with global standards is maintained through EU-GMP certified plants and innovative practices, while sustainability and quality are emphasized in all activities. International accreditations and partnerships are utilized to enhance global healthcare access.

Operational Areas
Healthcare → Alternative Medicine Products
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹11,803 Cr

    AKUMS · NSE

  • Share Price
    ₹741.05

    -1.18% today

  • Revenue
    ₹4,359 Cr

    FY 2025-26 · +5.9% YoY

  • EBITDA
    ₹502 Cr

    Margin 11.5%

  • Net Profit
    ₹269 Cr

    FY 2025-26 · -16.7% YoY

  • P/E (TTM)
    32.1x

    P/B 3.5x

  • ROE
    8.1%

    ROCE 12.5%

  • Debt / Equity
    0.04

    Interest cover 27.1x

  • Employee Count
    1,563

Products & Services of Unosource Pharma

Unosource Pharma offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and Nutraceuticals.

Pharmaceutical Formulations
Healthcare Products

Pharmaceutical formulations are developed and manufactured for global markets, covering areas such as anti-infectives and cardiovascular care

Nutraceuticals
Wellness Products

Nutraceuticals are produced and supplied for general wellness and specific health needs like beauty nutrition

Apps and channels of Unosource Pharma

its YouTube channel Akums Drugs and Pharmaceuticals Ltd. has 1.34K subscribers and 30 videos.

Akums Drugs and Pharmaceuticals Ltd.
YouTube 1.34K subscribers 30 videos Science & Technology
Open channel

Videos from Unosource Pharma

The most watched videos on Unosource Pharma's YouTube channel, Akums Drugs and Pharmaceuticals Ltd. (1.34K subscribers). Click a video to play it here.

Akums X Caregen | Dr. CYJ Hair Fillers
135 views
Akums - Annual General Meeting
112 views
Akums: Empowering Pharma Growth & Market Expansion
91 views
Akums | Growth is always beside you
77 views

More on Akums Drugs and Pharmaceuticals Ltd..

Board of directors of Akums Drugs And Pharmaceuticals Limited (Unosource Pharma)

Akums Drugs And Pharmaceuticals Limited is the primary company behind Unosource Pharma. The board of Akums Drugs And Pharmaceuticals Limited currently have 8 directors; the longest-serving is Sandeep Jain, appointed in 2004. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sandeep Jain
DIN 00323476
Managing Director19 Apr 200422 yrs 6 moAkums Drugs And Pharmaceuticals Limited
Sanjeev Jain
DIN 00323433
Managing Director19 Apr 200422 yrs 6 moAkums Drugs And Pharmaceuticals Limited
Kewal Kundanlal Handa
DIN 00056826
Director16 Mar 20224 yrs 7 moAkums Drugs And Pharmaceuticals Limited
Matangi Gowrishankar
DIN 01518137
Director16 Mar 20224 yrs 7 moAkums Drugs And Pharmaceuticals Limited
Satwinder Singh
DIN 00164903
Director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Sunil Kumar Thakur
DIN 03266370
Nominee Director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Sanjay Sinha
DIN 03627342
Whole-time director17 Jan 20242 yrs 9 moAkums Drugs And Pharmaceuticals Limited
Anilkumar Arvindlal Amin
DIN 10594012
Director04 Jun 20251 yr 5 moAkums Drugs And Pharmaceuticals Limited

IPO & Listings of Unosource Pharma

Unosource Pharma is a publicly listed company on the NSE with ticker symbol AKUMS in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: AKUMS
  • Listed entityAkums Drugs And Pharmaceuticals Limited
  • Exchange sectorPharmaceuticals

Financials of Unosource Pharma

Exchange-reported figures of Akums Drugs And Pharmaceuticals Limited, the listed company behind Unosource Pharma (NSE: AKUMS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,359 Cr
+5.8% YoY
EBITDA
₹502 Cr
+8.1% YoY
Profit After Tax
₹269 Cr
-16.7% YoY
Net Worth
₹3,313 Cr
+8.7% YoY
Total Assets
₹4,415 Cr
+37.0% YoY
Total Debt
₹157 Cr
+78.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Profit before tax382345(45.27)150(193)172114
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Balance sheet
Total assets4,4153,2222,7132,4042,1091,6471,439
Net worth3,3133,047710717622885722
Total debt15788.22565619395130175
Cash & bank1,68157627715010367.87147
Net working capital2,5461,4021,1491,042943659679
Cash flow
Cash from operations1,18146549817731.8513128.13
Cash from investing(930)(548)(331)(305)(235)(109)(190)
Cash from financing33.8872.79(108)125236(91.46)233
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3421,1671,1581,1601,0181,0241,0561,010
Revenue growth (YoY)+31.9%+13.9%+9.7%+14.8%-1.5%+0.5%--
Other income28.9130.3835.3034.3332.3726.7325.7619.34
EBITDA19517515012994.4812993.92121
EBITDA margin+14.5%+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%
Depreciation43.2141.0740.1239.6537.8636.9240.0044.52
Interest25.6824.7623.8923.7423.3023.144.545.13
Profit before tax15513912199.5765.6995.6475.1491.05
Tax40.1838.2639.8731.8922.9830.96(74.47)24.75
Net profit11510181.3567.6842.7164.6815066.30
EPS (₹)7.376.535.534.332.664.159.644.26
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Profit before tax148208(103)150(335)(195)75.85
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Balance sheet
Total assets2,5162,3741,7961,5211,3891,1761,262
Net worth2,4282,305144312186567712
Total debt59.2146.2926714614041.1335.80
Cash & bank77135673.318.8525.741.0072.48
Net working capital1,035530244148143230352
Cash flow
Cash from operations(2.15)91.0024894.0122855.57(21.75)
Cash from investing(24.97)(459)(165)(202)(298)(99.96)(242)
Cash from financing(3.00)375(20.74)89.9094.992.60302
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue395392338369309332329337
Revenue growth (YoY)+27.7%+18.0%+2.9%+9.3%-5.8%+4.8%--
Other income25.8026.1027.7329.6027.0828.5632.0533.84
Total expenses360344329348292288311303
EBITDA34.5748.519.0720.8716.9044.1017.7234.03
EBITDA margin+8.8%+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%
Depreciation13.5112.8012.4212.1510.6910.2510.0910.68
Interest3.002.482.592.462.082.912.632.29
Profit before tax43.8659.3321.7935.8631.2159.5037.0554.90
Tax11.2114.506.607.757.7414.649.4713.73

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 14 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3421,1671,1581,1601,0181,0241,0561,010
Revenue growth (YoY)+31.9%+13.9%+9.7%+14.8%-1.5%+0.5%--
Other income28.9130.3835.3034.3332.3726.7325.7619.34
EBITDA19517515012994.4812993.92121
EBITDA margin+14.5%+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%
Depreciation43.2141.0740.1239.6537.8636.9240.0044.52
Interest25.6824.7623.8923.7423.3023.144.545.13
Profit before tax15513912199.5765.6995.6475.1491.05
Tax40.1838.2639.8731.8922.9830.96(74.47)24.75
Net profit11510181.3567.6842.7164.6815066.30
EPS (₹)7.376.535.534.332.664.159.644.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
Other income12968.8234.0390.0722.8321.5027.49
Total expenses3,8573,6544,0813,4363,7772,4952,241
Employee cost754716647590508425439
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Depreciation15515312611394.6869.8466.68
Interest94.0734.6050.6146.2516.666.7419.93
Profit before tax382345(45.27)150(193)172114
Tax1261.48(46.07)52.4857.6848.8370.17
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus3,2833,016681689608884721
Shareholders' funds (net worth)3,3133,047710717622885722
Minority interest17.7716.6010.996.193.202.29(1.51)
Secured loans72.9513.6639153735895.90140
Unsecured loans84.4874.5617482.1237.0334.0735.02
Total debt15788.22565619395130175
Total liabilities4,4153,2222,7132,4042,1091,6471,439
Assets
Gross block2,4102,2421,8821,6831,5181,321993
Net block1,4561,3971,1911,0971,021904645
Capital work in progress17716319510331.0717.0156.60
Investments0.140.140.140.140.3919.545.84
Inventories756681630730722430398
Sundry debtors797770834845884531582
Cash & bank balances1,68157627715010367.87147
Loans & advances327247200154154109117
Total current assets3,5602,2751,9411,8791,8641,1381,244
Total current liabilities1,014873792837921479565
Net working capital2,5461,4021,1491,042943659679
Total assets4,4153,2222,7132,4042,1091,6471,439
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10111151.6155.1422.0791.7920.51
Net cash from operating activities1,18146549817731.8513128.13
Net cash from investing activities(930)(548)(331)(305)(235)(109)(190)
Net cash from financing activities33.8872.79(108)125236(91.46)233
Net change in cash285(9.86)59.44(3.53)33.07(69.72)71.28
Closing cash1,68157627715010367.87147
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA growth+8.1%+379.1%-55.8%+309.4%-146.1%+31.4%-
PBT growth+10.7%+9998.0%-+9998.0%-+51.3%+7.7%
Net income growth-16.7%+1660.6%-116.2%+152.3%-287.8%+194.2%-
Revenue CAGR (3Y)+6.1%+3.9%+15.4%+14.8%+30.5%+23.0%-
EBITDA CAGR (3Y)+31.8%--24.7%+8.2%-+22.4%-
Profitability & leverage
Net income margin+5.9%+8.4%+0.0%+2.7%-6.8%+4.5%+1.8%
Return on capital employed+12.5%+12.9%+1.2%+11.7%-9.4%+11.6%+9.3%
Return on net worth+8.1%+18.3%-2.2%+19.5%-33.3%+15.4%+6.0%
Debt / equity0.040.170.830.760.330.190.24
Long-term debt / equity0.020.060.240.180.030.020.01
Interest cover27.0711.12-176.4043.44-8.364.2818.75
Efficiency & per share
Fixed asset turnover1.872.002.342.282.662.352.43
Inventory turnover6.076.286.145.036.376.576.06
Debtors turnover5.565.134.984.235.194.894.15
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)216.41199.0149.5950.1386.956,801.285,554.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue395392338369309332329337
Revenue growth (YoY)+27.7%+18.0%+2.9%+9.3%-5.8%+4.8%--
Other income25.8026.1027.7329.6027.0828.5632.0533.84
Total expenses360344329348292288311303
EBITDA34.5748.519.0720.8716.9044.1017.7234.03
EBITDA margin+8.8%+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%
Depreciation13.5112.8012.4212.1510.6910.2510.0910.68
Interest3.002.482.592.462.082.912.632.29
Profit before tax43.8659.3321.7935.8631.2159.5037.0554.90
Tax11.2114.506.607.757.7414.649.4713.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
Other income11312494.1296.1558.4854.5165.52
Total expenses1,2581,1731,5901,1891,5241,060697
Employee cost218202175147136123124
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Depreciation45.5039.5532.6930.0027.7626.1025.26
Interest10.0415.3118.3113.183.650.824.34
Profit before tax148208(103)150(335)(195)75.85
Tax36.7246.8362.5224.8946.80(49.77)24.99
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus2,3972,275115283171566711
Shareholders' funds (net worth)2,4282,305144312186567712
Secured loans13.553.9322614612222.7135.80
Unsecured loans45.6642.3640.780.0018.0718.420.00
Total debt59.2146.2926714614041.1335.80
Total liabilities2,5162,3741,7961,5211,3891,1761,262
Assets
Gross block792683613532497463436
Net block425356317272253244242
Capital work in progress52.2356.748.6516.250.521.261.13
Investments36636613913914114965.35
Inventories23020216219717995.91123
Sundry debtors218206234256304212178
Cash & bank balances77135673.318.8525.741.0072.48
Loans & advances10569.2464.4358.9946.1943.02121
Total current assets1,324833533521555352494
Total current liabilities289303289373412122142
Net working capital1,035530244148143230352
Total assets2,5162,3741,7961,5211,3891,1761,262
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash76.4968.967.2325.490.1541.933.87
Net cash from operating activities(2.15)91.0024894.0122855.57(21.75)
Net cash from investing activities(24.97)(459)(165)(202)(298)(99.96)(242)
Net cash from financing activities(3.00)375(20.74)89.9094.992.60302
Net change in cash(30.11)7.5461.72(18.26)25.34(41.79)38.07
Closing cash77135673.318.8525.741.0072.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA growth-34.3%+194.8%-250.0%+126.9%-62.5%-658.0%-
PBT growth-28.6%+9998.0%-+9998.0%-71.6%--32.3%
Net income growth-26.4%+200.6%-168.3%+160.2%-447.0%+117.0%-
Revenue CAGR (3Y)+1.6%+4.1%+19.9%+20.4%+19.4%+12.0%-
EBITDA CAGR (3Y)-2.2%--13.1%+34.6%---
Profitability & leverage
Net income margin+8.3%+12.3%-11.5%+9.8%-32.9%-17.4%+6.9%
Return on capital employed+6.5%+10.7%-3.9%+21.2%-25.8%+4.5%+7.4%
Return on net worth+4.7%+13.2%-69.2%+92.8%-101.5%+17.3%+6.6%
Debt / equity0.020.130.910.570.220.050.06
Long-term debt / equity0.020.040.170.08-30,181.49-17,754.290.00
Interest cover22.0915.47-10.2419.57-0.94-0.3329.58
Efficiency & per share
Fixed asset turnover1.832.022.522.502.421.861.79
Inventory turnover6.257.228.056.848.447.656.43
Debtors turnover6.375.965.904.604.514.304.38
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)158.56150.5710.0621.7725.944,358.555,476.91

Top companies in Alternative Medicine Products

3 companies that operate in the same segment as Unosource Pharma (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Schwabe India
Homeopathic medicine manufacturing and online retail in India.
1898Noida, Uttar Pradesh, IndiaUSD 26.35 M1,192
Healthmug
Operates an online store specializing in ayurvedic and homeopathic medicines.
2016Delhi, Delhi, IndiaUSD 1.25 M16
Jiva Ayurveda
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness.
1992Faridabad, Haryana, IndiaUSD 10.08 M570
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Unosource Pharma

AKUMS: Q2 REVENUE 13.42B RUPEES VS 10.16B (YOY)
Exchange Update • 12 days ago
AKUMS: Q2 CONS NET PROFIT 1.13B RUPEES VS 408M (YOY)
Exchange Update • 12 days ago
AKUMS: Q2 EBITDA 1.95M RUPEES VS 934.8M (YOY); Q2 EBITDA MARGIN 14.51% VS 9.19% (YOY)
Exchange Update • 12 days ago
Akums Launches New Moisturization Formulations for Winter Skincare Season
Media Bulletins • 1 month ago
Akums Drugs And Pharmaceuticals: To Host Analyst And Investor Meeting On September 22 At 10 AM
Exchange Update • 1 month ago
Akums reports robust Q1 FY27 performance with 13.9% YoY Revenue growth - The Wire
The Wire • 3 months ago
Buy Akums Drugs and Pharmaceuticals; target of Rs 850: ICICI Securities
Moneycontrol • 3 months ago
AKUMS: Strong Q1 growth driven by CDMO, margin expansion, and strategic acquisition in cosmetics
Quartr • 3 months ago
Buzzing Stocks: Emcure Pharma gains 3% on USFDA EIR; PFC slips 3% after mixed Q1 earnings
Moneycontrol • 3 months ago
Q1 Results 08th Aug Highlights: Delhivery, Anant Raj, Apollo Micro Systems, Akums Drugs Pharma, Aditya Birla Fashion, Ceigall India, PNC Infratech Oswal Pumps to announce Q1 results - The HinduBusinessLine
Thehindubusinessline • 3 months ago
Premium access

Complete news archive for Unosource Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Unosource Pharma

Unosource Pharma was founded in 2013.

Unosource Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Unosource Pharma has 1,563 employees.

The primary company behind Unosource Pharma, Akums Drugs And Pharmaceuticals Limited, reported revenue of ₹4,488 Cr for FY 2026, up 6% year on year.

Akums Drugs and Pharmaceuticals Ltd. is recognized as a leading CDMO in the pharmaceutical sector, where operations are supported by advanced manufacturing facilities and RD capabilities. Products are exported to over 65 countries, with a focus on formulations for pharmaceuticals, nutraceuticals, and cosmetics. Compliance with global standards is maintained through EU-GMP certified plants and innovative practices, while sustainability and quality are emphasized in all activities. International accreditations and partnerships are utilized to enhance global healthcare access.

Unosource Pharma offers Pharmaceutical Formulations and Nutraceuticals.

Yes, Unosource Pharma is publicly traded on NSE under the ticker symbol AKUMS.

Unosource Pharma operates through Akums Drugs And Pharmaceuticals Limited.

The legal entities of Unosource Pharma currently have 10 directors, including Kewal Kundanlal Handa, Matangi Gowrishankar, Dharamvir Malik and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available